Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Review

Heart failure guidelines: What you need to know about the 2017 focused update

Lee Rodney Haselhuhn, MD, Daniel J. Brotman, MD and Ilan Shor Wittstein, MD
Cleveland Clinic Journal of Medicine February 2019, 86 (2) 123-139; DOI: https://doi.org/10.3949/ccjm.86a.18022
Lee Rodney Haselhuhn
Department of Medicine, Johns Hopkins University, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Daniel J. Brotman
Department of Medicine, Johns Hopkins University, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilan Shor Wittstein
Departments of Medicine and Cardiology, Johns Hopkins University, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 1

    Heart failure stages and functional classes

    NYHA class INYHA class IINYHA class IIINYHA class IV
    No physical limitationsSlight limitation of physical activityMarked limitation of physical activitySymptoms at rest
    Stage AStage BStage CStage D
    Patients at risk for heart failure
    No structural disease
    Structural disease
    No heart failure symptoms
    Structural disease
    Heart failure symptoms
    End-stage disease
    • NYHA = New York Heart Association

    • Reprinted from Okwuosa IS, Princewill O, Nwabueze C, et al. The ABCs of managing systolic heart failure: past, present, and future. Cleve Clin J Med 2016; 83(10):753-765. doi:10.3949/ccjm.83a.16006

    • View popup
    TABLE 2

    Recommendations for measuring biomarkers in heart failure

    Patient groupClassa
    At risk of heart failure
    BNP or NT-proBNP for preventionIIa
    Ambulatory with new-onset dyspnea
    BNP or NT-proBNP for diagnosisI
    With NYHA class II-IV symptoms
    BNP or NT-proBNP for prognosisI
    Other biomarkers of myocardial injury or fibrosisb for prognosisIIb
    With acute dyspnea in the emergency department
    BNP or NT-proBNP for diagnosisI
    BNP or NT-proBNP, and cardiac troponin for prognosisI
    Hospitalized for acute decompensated heart failure
    BNP or NT-proBNP, and cardiac troponin for prognosisI
    BNP or NT-proBNP before discharge for prognosisIIa
    Other biomarkers of myocardial injury or fibrosisb for prognosisIIb
    • ↵a Class of recommendation (I strong, Ila moderate, Ilb weak).

    • ↵b For example, soluble ST2 receptor, galectin-3, and high-sensitivity troponin.

    • BNP = B-type natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association

    • Information from reference 1.

    • View popup
    TABLE 3

    Recommendations for patients with heart failure with preserved ejection fraction

    RecommendationClassa
    Aldosterone receptor antagonistsbIIb
    Angiotensin II receptor blockersIIb
    Routine use of nitrates or phosphodiesterase-5 inhibitors is ineffectiveIII
    • ↵a Class of recommendation (I strong, Ila moderate, Ilb weak, III no benefit).

    • ↵b In patients with ejection fraction ≥ 45%, elevated B-type natriuretic peptide levels or heart failure admission within 1 year, estimated glomerular filtration rate > 30 mL/ min, creatinine < 2.5 mg/dL, potassium < 5.0 mmol/L.

    • Information from reference 1.

    • View popup
    TABLE 4

    Recommendations for managing blood pressure in heart failure

    Patient groupClassa
    With hypertension at increased risk
    < 130/80 mm Hg should be the optimal blood pressureI
    With heart failure with reduced ejection fraction
    Guideline-directed medical treatment titrated to attain a blood pressure of < 130/80 mm HgI
    Nondihydropyridine calcium channel blockers not recommendedIII
    With heart failure with preserved ejection fraction and symptoms of volume overload
    Diuretics to control hypertensionI
    With heart failure with preserved ejection fraction and persistent hypertension after management of volume overload
    Guideline-directed medical therapy titrated to attain systolic blood pressure < 130 mm Hg. Although there are limited data to guide the choice of antihypertensive therapy in HFpEF, preferred agents include RAAS inhibition with ACE-I, ARB, and mineralocorticoid receptor antagonists (spironolactone).I
    Nitrates not recommended in HFpEF, unless given for symptomatic coronary artery disease, due to association with a signal of harm or decreased exercise tolerance.III
    • ↵a Class of recommendation (I strong, III no benefit).

    • ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; HFpEF = heart failure with preserved ejection fraction; RAAS = renin-angiotensin-aldosterone system

    • Information from reference 1.

    • View popup
    TABLE 5

    Studies of sleep-disordered breathing in heart failure

    SERVE-HF54 (Treatment of Sleep-Disordered Breathing With Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients With Heart Failure)
    Aim: To determine whether adaptive servo-ventilation, a form of noninvasive ventilation that automatically adjusts to give the right amount of inspiratory pressure support upon inhalation, vs standard therapy alone could decrease morbidity and mortality in heart failure with reduced ejection fraction and predominantly central sleep apnea as was suggested by a post hoc analysis of a previous trial.52
    Design: Multicenter, single-blind randomized controlled trial, N = 1,325
    Primary end point: Composite end point of time to event for death from any cause, lifesaving cardiovascular intervention (transplant, left ventricular assist device, defibrillation), or unplanned hospitalization for heart failure over 5 years.
    Findings: Not only was there no significant change in the primary end point, the treatment arm actually showed a significant increase in cardiovascular (hazard ratio 1.34, P= .0006) and all-cause (hazard ratio 1.28, P= .01) mortality. One prominent but hotly debated hypothesis is that the Cheyne-Stokes respirations in central sleep apnea are compensatory in severe heart failure, perhaps allowing the pulmonary musculature to rest, attenuating sympathetic nervous system activity, and avoiding acidosis due to hypercapnia.
    SAVE56 (Sleep Apnea Cardiovascular Endpoints)
    Aim: To determine whether continuous positive airway pressure (CPAP) plus standard therapy vs standard therapy alone would decrease cardiovascular events in patients with moderate to severe obstructive sleep apnea and known coronary or cerebrovascular disease.
    Design: Multicenter, randomized controlled trial, N = 2,717
    Primary end point: Composite end point of death from cardiovascular cause, myocardial infarction, stroke, or hospitalization for unstable angina, heart failure, or transient ischemic attack over nearly 4 years.
    Secondary end points: Cardiovascular secondary end points included the individual components of the primary composite end point, other composites of cardiovascular events, revascularization procedures, new-onset atrial fibrillation, new-onset diabetes mellitus, and death from any cause. Noncardiovascular end points included daytime sleepiness, snoring, mood (depression, anxiety), and quality-of-life scores.
    Findings: Contrary to prior observational studies and despite a marked improvement in apneic-hypopneic events with CPAP (29/hour to 3.7/hour), no significant difference in the primary composite end point (17% vs 15.4%, P= .34) or cardiovascular secondary end points was evident. Significant improvement was seen in the noncardiovascular secondary end points such as daytime sleepiness, snoring, mood (depression, anxiety), and quality-of-life scores.
    • View popup
    TABLE 6

    Recommendations on sleep apnea in heart failure

    Patient groupClassa
    With New York Heart Association (NYHA) class II-IV heart failure and suspicion of sleep-disordered breathing or excessive daytime sleepiness
    A formal sleep assessment to distinguish obstructive vs central sleep apnea is reasonableIIa
    With cardiovascular disease and obstructive sleep apnea
    Continuous positive airway pressure may be reasonable to improve sleep apnea and reduce daytime sleepinessIIb
    With NYHA class II-IV heart failure with reduced ejection fraction and central sleep apnea
    Adaptive servo-ventilation causes harmIII
    • ↵a Class of recommendation (IIa moderate, IIb weak, III harm).

    • Information from reference 1.

    • View popup
    TABLE 7

    Iron deficiency in heart failure: Upcoming trials

    FAIR-HF271 (Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity and Mortality)
    Estimated completion: October 2020
    AFFIRM-AHF72 (Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency)
    Estimated completion: June 2019
    HEART-FID73 (Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency)
    Estimated completion: January 2021
    IRONMAN74 (Effectiveness of intravenous iron treatment vs standard care in patients with heart failure and iron deficiency)
    Estimated completion: February 2021
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 86 (2)
Cleveland Clinic Journal of Medicine
Vol. 86, Issue 2
1 Feb 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Heart failure guidelines: What you need to know about the 2017 focused update
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Heart failure guidelines: What you need to know about the 2017 focused update
Lee Rodney Haselhuhn, Daniel J. Brotman, Ilan Shor Wittstein
Cleveland Clinic Journal of Medicine Feb 2019, 86 (2) 123-139; DOI: 10.3949/ccjm.86a.18022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Heart failure guidelines: What you need to know about the 2017 focused update
Lee Rodney Haselhuhn, Daniel J. Brotman, Ilan Shor Wittstein
Cleveland Clinic Journal of Medicine Feb 2019, 86 (2) 123-139; DOI: 10.3949/ccjm.86a.18022
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • COMMON, COSTLY, AND DEBILITATING
    • BIOMARKERS FOR PREVENTION
    • BIOMARKERS FOR PROGNOSIS OR ADDED RISK STRATIFICATION
    • PHARMACOLOGIC TREATMENT FOR STAGE C HFpEF
    • ALDOSTERONE ANTAGONISTS FOR HFpEF
    • IRON DEFICIENCY IN HEART FAILURE
    • HYPERTENSION IN HEART FAILURE
    • SLEEP-DISORDERED BREATHING IN HEART FAILURE
    • POTENTIAL APPLICATIONS IN ACUTE DECOMPENSATED HEART FAILURE
    • SHOULD WE USE BIOMARKER TARGETS TO GUIDE THERAPY IN ADHF?
    • SHOULD ALDOSTERONE ANTAGONISTS BE USED IN ACUTE HFpEF?
    • SHOULD INTRAVENOUS IRON BE GIVEN DURING ADHF ADMISSIONS?
    • INTERNISTS ARE KEY
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • High-output heart failure from arteriovenous dialysis access: A structured approach to diagnosis and management
  • Direct oral anticoagulants: Challenging prescribing scenarios in everyday practice
  • IgA nephropathy: Update on pathogenesis and treatment
Show more Review

Similar Articles

Subjects

  • Cardiology
  • Critical Care
  • Drug Therapy
  • Emergency Medicine
  • Hospital Medicine
  • Preventive Care

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire